EZH2 and breast carcinoma: The published literature has demonstrated that the upregulation of the enhancer of zeste homolog 2 (EZH2), involved in cell cycle regulation, is correlated with tumor invasiveness and aggressive clinical behavior as well as the poor prognosis of breast cancers [103].